TULSA-PRO®
Localized Prostate Cancer
Key Facts
About Profound Medical
Profound Medical's mission is to transform patient care through precise, predictable, and radiation-free ablation therapies. Its key achievement is the FDA-cleared and CE-marked TULSA-PRO® system, which recently demonstrated superior functional preservation versus robotic prostatectomy in the pivotal CAPTAIN randomized controlled trial. The company's strategy involves direct commercialization and strategic partnerships to penetrate the global prostate disease market while exploring new indications for its Sonalleve® platform in oncology.
View full company profileAbout Profound Medical
Profound Medical's mission is to transform patient care through precise, predictable, and radiation-free ablation therapies. Its key achievement is the FDA-cleared and CE-marked TULSA-PRO® system, which recently demonstrated superior functional preservation versus robotic prostatectomy in the pivotal CAPTAIN randomized controlled trial. The company's strategy involves direct commercialization and strategic partnerships to penetrate the global prostate disease market while exploring new indications for its Sonalleve® platform in oncology.
View full company profileAbout Profound Medical
Profound Medical's mission is to transform patient care through precise, predictable, and radiation-free ablation therapies. Its key achievement is the FDA-cleared and CE-marked TULSA-PRO® system, which recently demonstrated superior functional preservation versus robotic prostatectomy in the pivotal CAPTAIN randomized controlled trial. The company's strategy involves direct commercialization and strategic partnerships to penetrate the global prostate disease market while exploring new indications for its Sonalleve® platform in oncology.
View full company profileAbout Profound Medical
Profound Medical's mission is to transform patient care through precise, predictable, and radiation-free ablation therapies. Its key achievement is the FDA-cleared and CE-marked TULSA-PRO® system, which recently demonstrated superior functional preservation versus robotic prostatectomy in the pivotal CAPTAIN randomized controlled trial. The company's strategy involves direct commercialization and strategic partnerships to penetrate the global prostate disease market while exploring new indications for its Sonalleve® platform in oncology.
View full company profileTherapeutic Areas
Other Localized Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Karolinska Institutet Prostate Cancer IRE Study | AngioDynamics | Randomized Controlled Trial |
| SBRT for Prostate Cancer | Accuray | Clinical Adoption |
| ORCA-010 | ORCA Therapeutics | Phase I/IIa |